

Gastroenterology Enrollment Form

Fax: 949-340-8008

Rep:

Phone: 949-305-0788

Whole Health Pharmacy

PATIENT INFO	RMATION		PRESCRIBER INFORMATION		
Please complete the following or send patient demographic sheet			Prescriber Name		
Patient Name			DEA		-
Address			NPI		-
Address 2			Address		-
City, State, Zip			City, State, Zin		-
City, State, ZipMobile Phone			City, State, Zip PhoneFax		-
DOBLast Four of SSGender			Contact Person		-
Language Prefere	ence				
Clinical Diagnosis: please fax or email relevant clinical notes, labs, tests, and previous medical history to expedite prior authorization					
Diagnosis - Please include diagnosis name with ICD-10 code			Additional information Therapy New Reauth		
K72.90 Hepatic er			Weightkg/lbs Height		
B18.1 Chronic He			Allergies		
	wel syndrome with Diarrhea	ations	Lab Data Prior Therapies		
 K50.90 Crohn's disease, unspecified without complications K51.90 Ulcerative colitis, unspecified without complications 			Concomitant Medications		
□ Other Diagnosis: ICD-10 Code			Additional Comments		
Description			Injection Training Required: Yes No		
Date of Diagnosis					
Has TB test been performed? Yes No					
Does the patient have an active infection? Yes No					
Medication	Deco/Strongth	PRESCRIPT	ION INFORMATION Directions	Quantity	Refills
	Dose/Strength	□ Take 1 tablet PO		Quantity	Rennis
🗆 Xifaxan	□ 20011g □ 550mg	□ Take 1 tablet PO			
Baraclude	□ 0.5mg	Take 1 tablet PO		□ 30 days	
	□ 300mg	Take 1 tablet PO		□ 30 days	
Vemlidy	□ 25mg	Take 1 tablet PO		□ 30 days	
🗆 Cimzia	Starter Kit	□ Inject 400mg SQ on days 0,14, & 28		□ 28 days	
	200 mg PFS 1	Inject 400mg SQ every 28 days		,	
Entyvio	300mg/20ml vial 1	□ Infuse 300mg IV on weeks 0,2, & 6			
	□ Infuse 300mg I				
		 □ Inject 40mg SQ every other week □ Inject 40mg SQ once weekly □ Inject 80mg SQ every other week □ Inject 160mg SQ on day 1 then inject 80mg on day 15 then start 			
Humira CF	□ 40mg/0.4 ml Prefilled Syringe □ 40mg/0.4 ml Pens				
	□ 40mg/0.4 mi Pens				
	□ Crohn's Starter kit		e (Crohn's Starter pack)		
Inflectra	□ 100mg vial		V on weeks 0,2, & 6 (starter dose)		
	5	□ Infuse 5mg/kg I			
Remicade	□ 100mg vial	□ Infuse 5mg/kg IV on weeks 0,2, & 6 (starter dose)			
		□ Infuse 5mg/kg I			
Renflexis	□ 100mg vial		V on weeks 0,2, & 6 (starter dose)		
	_	Infuse 5mg/kg I			
	□100mg/ ml Smartject	Inject 200mg SQ	on week 0. Then inject 100mg SQ on weeks 2, & 6		
Simponi	Autojector	(Starter)			
	100mg/ml PFS	Inject 100mg SQ every 4 weeks			
Stelara	□ 130mg/26 ml solution		e: _ 260mg _ 390mg _ 520mg		
	Single dose vial	As initial IV dose as directed by prescriber			
		 Inject 90mg SQ every 8 weeks (begin dosing 8 weeks after IV induction dose) Maintenance 			
🗆 Xeljanz	□ 5 mg tablets □ Take 5 mg twice			□ 30 days	
	\square 10 mg tablets	Take 10 mg twic			
Xeljanz XR	□ 11 mg tablets	□ Take 11 mg by n	nouth every day	□ 30 days	
	22 mg tablets		nouth every day for 16 weeks		
Zeposia	□ 7 day Starter Pack	Days 1-4 Take 0		1 Starter Pack	
	 □ Starter Kit (1 month supply) □ 0.92 mg maintenance 		.46 mg once daily after Take 0.92 mg once daily	20.1	
		□ Take 1 capsule b		□ 30 days	
🗆 Other					
	I ⊐ Office □ Other		Date: Need by Date		
Ship to: Date:Need by Date * Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s) and to sign any necessary forms on my behalf as					
my authorized agent, including the receipt of any required prior authorizations forms and the receipt and submission of patient tab values and other patient data, in the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize the pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.					
□ Product Substitution permitted □ Dispense as Written					
Prescriber's Signatur			Date:		
CONFIDENTIALITY STATEMENT: This communication is intended for use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination distribution, or copying of the communication is strictly prohibited. If you have received					
this communication in error, please notify us immediately by telephone					